Last updated 16 days ago

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

760 patients around the world
Available in Spain, Brazil
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Pfizer
7Research sites
760Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Instituto de Educação, Pesquisa e Gestão em Saúde
Avenida Das Americas 06205 Loj e Barra da Tijuca Rio de Janeiro RJ 22793-080
Hospital Japonês Santa Cruz
Recruiting
Rua Santa Cruz, 398 Vila Mariana, São Paulo
Centro de Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho
Jau, 17210080
Ambulatório Américas Medical City
Río de Janeiro
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa
Recruiting
Porto Alegre, 90110-270
Hospital Mãe de Deus - Porto Alegre
Recruiting
R. José de Alencar, 286 - Menino Deus, Porto Alegre - RS, 90880-481, Brazil
Hospital Amaral Carvalho
R. Doná Silvéria, 150 - Chácara Braz Miraglia, Jaú - SP, 17210-080, Brazil
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy